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Abstract
 
Aims
 
Hyperproinsulinaemia is associated with obesity and is a risk factor for Type 2 diabetes. We explored the dynamics
of proinsulin and insulin and postprandial effects on glucose and lipids in subjects who had undergone gastric bypass
(GBP) surgery compared with morbidly obese (MO) subjects and normal weight control subjects (NW).
 
Methods
 
Subjects free from diabetes were recruited: 10 previously MO subjects [body mass index (BMI) 
 
±
 
 
 
SD
 
,
34.8 
 
±
 
 6.2 kg/m
 
2
 
] who had undergone GBP surgery, 10 MO subjects (BMI 44 
 
±
 
 3.1 kg/m
 
2
 
) and 12 NW control subjects
(BMI 23.2 
 
±
 
 2.4 kg/m
 
2
 
). After an overnight fast, a standard meal (2400 kJ) was ingested and glucose, proinsulin, insulin
free fatty acids and triglycerides were determined up to 180 min.
 
Results
 
Fasting proinsulin was similar in the GBP group and NW control subjects, but threefold increased in MO
subjects (
 
P < 
 
0.05). Postprandial AUC for glucose was similar in the three groups and AUC for proinsulin was high in
MO, intermediate in the GBP group and lowest in NW control subjects (
 
P
 
 for trend = 0.020). Postprandial proinsulin at
60 min was similar in the GBP group and MO subjects and twofold higher than in NW control subjects. Postprandial
proinsulin at 180 min was normal in the GBP group, but fivefold increased in MO subjects (
 
P = 
 
0.008). Insulin increased
rapidly at 30 min in the GBP group and was normal at 90 min, whereas insulin was still increased at 90–180 min in the
MO subjects (
 
P < 
 
0.001).
 
Conclusions
 
MO subjects, free from diabetes, have elevated proinsulin concentrations in the fasting as well as the
postprandial phase. After GBP surgery markedly lower fasting and postprandial proinsulin concentrations were
observed, although BMI was higher compared with NW control subjects.
Diabet. Med. 24, 1213–1220 (2007) 
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Introduction
 
Obesity is associated with insulin resistance [1], fasting
hyperinsulinaemia [2] and fasting hyperproinsulinaemia [3].
In addition to insulin resistance [4], the hyperproinsulinaemia,
which reflects pancreatic B-cell strain, is associated with
increased risk of Type 2 diabetes mellitus (T2DM) in men [5,6]
and women [7], and with coronary heart disease (CHD)
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morbidity [8–10] and mortality [10] in men. Elevated proinsulin
predicts conversion to T2DM independent of peripheral
insulin resistance and early insulin response during a glucose
tolerance test [5,6]. Moderate weight loss is associated with
improved insulin sensitivity and lowered hyperinsulinaemia
[11] and a reduced incidence of T2DM [12,13]. Pronounced
weight loss after gastric bypass (GBP) surgery in subjects with
morbid obesity is associated with a marked improvement in
insulin sensitivity [14], lower fasting hyperinsulinaemia [15],
lower postprandial hyperinsulinaemia [16] and a markedly
reduced conversion to T2DM over 10 years of follow-up [17].
GBP surgery is also known to cause rapid transit of nutrients
to the bowel, with rapid elevations of glucose and insulin. To
our knowledge, there is no report on postprandial proinsulin
and insulin and their interrelationship in morbid obesity after
GBP surgery. The aim of the present study was to investigate
fasting and postprandial proinsulin and insulin responses,
effects on glucose, free fatty acids (FFA) and triglycerides (TG)
in previously morbidly obese subjects with GBP-induced
weight loss, in comparison with subjects with morbid obesity
(MO) and normal weight (NW) control subjects.
 
Patients and methods
 
Study subjects
 
Patients were recruited from the out-patient clinic for obesity
care, University Hospital, Uppsala, Sweden, where preassessments
before and long-term check-up visits of patients after surgery
were performed. Control subjects were recruited locally. All
subjects were White. Exclusion criteria for all three groups were
established diabetes or use of glucose-lowering agents, as well
as use of ACE-inhibitors, angiotensin II receptor blockers or 
 
β
 
-
blockers, to avoid possible influence on glucose, proinsulin and
insulin status.
Three groups of subjects were compared
A: Ten surgically treated patients considered weight stable after
weight loss due to GBP surgery, with body mass index (BMI)
34.8 
 
±
 
 6.2 kg/m
 
2
 
 (mean 
 
±
 
 
 
SD
 
), who had undergone GBP surgery
1–5 years (mean 4.1 years) before study. The mean presurgery
BMI was 45.3 
 
±
 
 7.6 kg/m
 
2
 
. The mean absolute weight loss was
31.8 kg (range 16–47 kg). The mean fall in BMI after surgery
was 10.5 kg/m
 
2
 
 (23%).
B: Ten surgically untreated patients with MO, with BMI
44.0 
 
±
 
 3.1 kg/m
 
2
 
. These patients had refused surgery or were on
the waiting list for surgery after preassessment. Their mean BMI
was similar to the presurgery BMI in the group of subjects who
underwent GBP surgery (
 
P
 
 for difference = 0.59).
C: Twelve healthy NW control subjects, BMI 23.2 
 
±
 
 2.4 kg/m
 
2
 
.
Age and sex distribution were similar in the three groups (Table 1).
The local ethics committee at the Faculty of Medicine
approved the study protocol. All patients gave informed consent.
 
GBP surgery procedure
 
Roux-en-Y GBP excludes the stomach and duodenum from the
passage of food [18]. The flaccid part of the lesser omentum
was opened and the first gastric vessel divided at the lesser
curvature, just below the fat pad, to create a small gastric pouch
(2 
 
×
 
  3  cm). The opening for the first horizontal stapler was
made very close to the wall of the stomach, taking care not
damage the nerve-vessel bundle containing the vagal nerve. The
pouch was then totally separated from the main stomach,
which was left in the abdomen. The small bowel was divided
30 cm distal to the ligament of Treitz and the distal end con-
nected to the small gastric pouch. This jejunal limb, the so-called
Roux limb, was made at least 50 cm long and placed behind the
excluded stomach and transverse colon. Small bowel continuity
was maintained by an entero-enterostomy between the Roux
limb and the previously divided proximal jejunum. This created
the Y-shaped junction where the ingested food, via the Roux
limb, and the gastric acid and bile are mixed. The procedure
was done under general anaesthesia, through a short upper-
midline incision.
Table 1 Clinical characteristics in morbidly obese subjects, obese subjects after GBP surgery and normal weight control subjects in the fasting state of 
the study
 
Morbidly obese 
(A)
GBP treated 
(B)
Control group 
(C)
Group A vs. B 
P-value
Group B vs. C 
P-value
Group A vs. C 
P-value
Sex (women/men) 5/5 5/5 6/6 — — —
Age (years) 41.6 ± 6.8 44.7 ± 5.3 41.1 ± 7.5 0.272 0.218 0.872
Body mass index (kg/m2) 44.0 ± 3.1 34.8 ± 6.2 23.2 ± 2.4 0.005 < 0.001 < 0.001
Weight (kg) 133.8 ± 20.2 106.1 ± 28.9 70.9 ± 12.5 0.023 0.001 < 0.001
Height (cm) 174.1 ± 12.1 173.5 ± 13.6 174.2 ± 9.6 0.918 0.882 0.974
f-P-glucose (mmol/l) 5.3 ± 0.6 5.2 ± 0.7 4.8 ± 0.6 0.721 0.225 0.098
HbA1c (%) 4.5 ± 0.3 4.5 ± 0.2 4.2 ± 0.2 0.800 0.018 0.018
f-P-proinsulin (pmol/l) 19.4 ± 18.1 7.0 ± 3.5 5.9 ± 7.4 0.047 0.680 0.028
f-P-insulin (pmol/l) 56.4 ± 28.2 24.6 ± 13.8 19.8 ± 13.2 0.005 0.408 0.001
PIR 0.34 0.28 0.30 0.74 0.33 0.26
f-P-FFA (mmol/l) 0.96 ± 0.32 0.74 ± 0.13 0.78 ± 0.32 0.052 0.716 0.182
f-P-TG (mmol/l) 1.97 ± 1.00 1.37 ± 0.70 0.91 ± 0.65 0.137 0.128 0.007
Data given are arithmetic mean ± SD.
f, Fasting; P, plasma; PIR, proinsulin to insulin ratio; FFA, free fatty acids; TG, triglycerides; GBP, gastric bypass.
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Test meal
 
The meal was composed bearing in mind the amount of food it
was possible to eat due to the reduced gastric volume after GBP
surgery, as follows: a hamburger containing minced beef 75 g,
oatmeal 8 g, potato flour 2.5 g, milk 28 g, boiled egg 10 g and
onion 5 g; brown sauce 70 g; boiled potatoes 130 g; and carrot
75 g. Dessert consisted of oat bread 40 g with margarine 13 g
and raspberry jam 17 g. Participants drank 200 ml of water
directly after the meal. The total energy content was 2400 kJ
(570 kcal), consisting of: carbohydrates 68.2 g, fat 22.3 g,
proteins 24.6 g and fibre 6.4 g.
 
Test meal procedures
 
After an overnight fast for 17 h the standardized test meal was
ingested at 13.00 h in the obesity out-patient clinic, allowing
supervision of food intake, which was finished within 15 min.
Blood samples were collected, centrifuged and freshly frozen
immediately before the test meal and thereafter at 30, 60, 90,
120 and 180 min after ingestion. Data were collected on
preprinted Case Report Forms.
 
Clinical measurements
 
Weight (kg) and height (m) were measured on standardized,
calibrated scales and BMI (kg/m
 
2
 
) was calculated. All patients
completed a standardized questionnaire, including questions
concerning their health status and smoking habits.
 
Laboratory analyses
 
At the laboratory of the Department of Public Health and
Caring Sciences/Geriatrics, University Hospital, Uppsala, plasma
proinsulin and insulin concentrations were determined using
the Proinsulin ELISA and the Insulin ELISA immunoassays
(Mercodia AB, Uppsala, Sweden) on a Bio-Rad Coda automated
EIA analyser (Bio-Rad Laboratories, Hercules, CA, USA).
Concentrations of serum FFA were determined using the Wako
NEFA C-test kit (Wako Chemicals GmbH, Neuss, Germany)
and serum TG by a lipase and quinoneimine dye method
(Konelab) on a Konelab analyser (Thermo Clinical Laboratory
Systems Oy, Vantaa, Finland). At the Department of Medical
Sciences, University Hospital in Uppsala, plasma glucose con-
centrations were determined using a routine glucose oxidase
technique (Beckman Glucose Analysers; Beckman, Fullerton,
CA, USA).
All plasma samples before and after the meal for all subjects
were analysed as one batch, thus avoiding drift of determinations.
Basal routine tests for concentrations of HbA
 
1c
 
, aspartate
aminotransferase, alanine aminotransferase, creatinine, sodium,
potassium, haemoglobin and white cell count were analysed
using routine methods at the Department of Clinical Chemistry,
University Hospital, Uppsala.
 
Statistics
 
All analyses were defined 
 
a priori
 
. Results are given as arithmetic
mean with 
 
SD
 
 and 
 
SEM
 
. 
 
ANOVA
 
 and Students 
 
t
 
-test were used
for group comparisons. Tests were two-tailed and a 
 
P
 
-value
< 0.05 was considered significant. Test meal data are given
as absolute concentrations (Table 2) and changes in con-
centrations (Fig. 1a–e). Statistical analyses were performed
using changes from basal concentrations, because absolute
differences in basal concentrations of variables (glucose,
proinsulin, insulin, TG and FFA) were expected between groups.
Areas under the curve (AUC) for glucose, proinsulin, insulin,
FFA and TG were also calculated for group comparisons.
Statistical software JMP 3.0 for PC (SAS Corp., Cary, NC, USA)
was used.
A power calculation indicated the need for 10 persons in each
group to detect a difference of 20% in changes of proinsulin
concentrations, with an 
 
α
 
 error level of 5% and a power of
80% for a two-tailed Student’s 
 
t
 
-test.
 
Results
 
Fasting data
 
Clinical characteristics of the study subjects are presented
in Table 1. Fasting glucose concentrations and HbA
 
1c
 
 values
were within the normal reference ranges in all subjects. The
mean fasting plasma glucose concentration was 0.4 mmol/l
higher (non-significant) in the GBP group and 0.5  mmol/l
higher in the MO group compared with the NW control
subjects. HbA
 
1c
 
 was 0.3% higher in both the GBP and
MO groups compared with NW control subjects (
 
P < 
 
0.05
for both).
Fasting proinsulin and insulin did not differ between the
GBP and NW control subjects, whereas proinsulin and insulin
concentrations were significantly higher in the MO group
compared with the GBP and NW control subjects, respectively.
The mean fasting FFA value in the MO and GBP groups
was not significantly different. TGs were higher in MO group,
as expected.
 
Postprandial data
 
Absolute concentrations of glucose, proinsulin, insulin, FFA
and TG are shown in Table 2.
 
Glucose
 
The AUC (mean 
 
±
 
 
 
SD
 
) for glucose (mmol 
 
×
 
 min) did not differ
between the MO group (270 
 
±
 
 92), the GBP group (310 
 
±
 
 110)
and NW control subjects (250 
 
±
 
 130) (
 
P
 
 for trend = 0.27).
Data for changes in glucose are presented in Fig. 1a. The
glucose concentrations were markedly increased during the
early phase (0–60 min) in the GBP group (rapid stomach transit)
compared with the MO group and NW control subjects. During
the intermediate (60–120  min) and the late (120–180  min)
phases after ingestion, the reduction in glucose concentrations
was larger in the GBP group compared with the MO group and
NW control subjects. The MO group and NW control subjects
had similar postprandial glucose responses.
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Proinsulin
 
The AUC (mean 
 
±
 
 
 
SD
 
) for proinsulin (pmol 
 
× 
 
min) was largest
in the MO group (7600 
 
±
 
  5300), intermediate in the GBP
group (5300 
 
±
 
 2700) and lowest in NW control subjects (3000
 
±
 
 1600) (
 
P
 
 for trend = 0.02). Data for changes in proinsulin are
shown in Fig. 1b. In the early phase, proinsulin concentra-
tions were higher in the GBP and MO groups compared
with NW control subjects. In the intermediate phase, plasma
proinsulin began to decrease in the GBP group, but was still
increasing in the MO group. In the late phase, concentrations
of plasma proinsulin were significantly lower in the GBP group,
similar to the NW control subjects, but were still high in
the MO group.
 
Insulin
 
The AUC (mean 
 
±
 
 
 
SD
 
) for insulin (pmol 
 
×
 
 min) was highest
in the MO group (41 000 
 
±
 
 9900), intermediate in the GBP
group (32 000 
 
±
 
 16 500) and lowest in NW control subjects
(18 000 
 
±
 
 8300) (
 
P
 
 for trend < 0.001). Data for changes in
insulin are presented in Fig. 1c. The GBP group had a rapid
increase in insulin concentrations in the early phase (peak
at 30 min) compared with the MO group. Insulin rapidly
decreased in the GBP group in the intermediate phase. The
late-phase insulin response was similar in the GBP group
and NW control subjects. In the MO group the late insulin
response was four times higher compared with the GBP
group.
 
Proinsulin to insulin ratio
 
The proinsulin to insulin ratio decreased identically in all three
groups during the first 30 min. The mean ratio decreased from
approximately 0.32–0.10, with no significant difference
between groups (
 
P = 
 
0.48 and 0.39).
 
Free fatty acids
 
The AUC (mean 
 
±
 
 
 
SD
 
) for FFA (mmol 
 
×
 
 min) did not differ
between the MO group (84 
 
±
 
 31), the GBP group (68 
 
±
 
 24)
and NW control subjects (63 
 
±
 
 54) (
 
P
 
 for trend = 0.44).
FFA absolute concentrations, shown in Table 2, were higher
(statistically significantly at 30, 60 and 90 min; 
 
P
 
 = 0.03–0.007)
at each postprandial time point except at 180 min in the MO
group compared with the GBP group and NW control subjects.
Prior to 180 min, the FFA values were all lower in the GBP group
compared with the NW control subjects and the MO group.
No significant differences were observed regarding post-
prandial changes in circulating FFA and concentrations
between the three groups, except at 180 min, where FFA were
higher in the GBP group (Fig. 1d).
 
Triglycerides
 
The AUC (mean 
 
±
 
 
 
SD
 
) for TG (mmol 
 
×
 
 min) was greatest in the
MO group (32 
 
±
 
 29), intermediate in the GBP group (16 
 
±
 
 22)
and lowest in NW control subjects (8 
 
±
 
 15), although the
differences did not reach statistical significance (
 
P
 
 for trend
Table 2 Postprandial test meal data in morbidly obese subjects, obese subjects after GBP surgery and normal weight controls
Time points
0 min 30 min 60 min 90 min 120 min 180 min
MO group
P-glucose (mmol/l) 5.3 ± 0.6 7.2 ± 0.7 7.6 ± 0.8 7.2 ± 1.0 6.7 ± 0.7 6.0 ± 0.9
P-proinsulin (pmol/l) 19.4 ± 18.1 36.3 ± 23.8 59.7 ± 36.8 73.1 ± 59.6 79.4 ± 64.7 70.1 ± 56.6
P-insulin (pmol/l) 56.4 ± 28.2 325 ± 120 424 ± 92.4 355 ± 145 281 ± 132 151 ± 70.2
P-FFA (mmol/l) 0.96 ± 0.32 0.86 ± 0.31 0.50 ± 0.25 0.35 ± 0.14 0.30 ± 0.08 0.33 ± 0.09
P-TG (mmol/l) 1.97 ± 1.00 1.97 ± 0.96 1.91 ± 0.89 2.14 ± 0.97 2.26 ± 0.99 2.51 ± 1.15
GBP group
P-glucose (mmol/l) 5.2 ± 0.7 10.6 ± 1.7 9.6 ± 1.9 7.0 ± 1.7 5.7 ± 1.2 5.0 ± 0.9
P-proinsulin (pmol/l) 7.0 ± 3.5 41.0 ± 20.6 57.9 ± 31.0 46.2 ± 22.9 33.2 ± 16.6 19.8 ± 9.7
P-insulin (pmol/l) 24.6 ± 13.8 558 ± 316 379 ± 245 143 ± 69.6 63.0 ± 30.6 34.8 ± 17.4
P-FFA (mmol/l) 0.74 ± 0.13 0.54 ± 0.15 0.20 ± 0.06 0.18 ± 0.04 0.23 ± 0.06 0.50 ± 0.14
P-TG (mmol/l) 1.37 ± 0.70 1.42 ± 0.76 1.41 ± 0.55 1.44 ± 0.62 1.49 ± 0.63 1.59 ± 0.65
NW control group
P-glucose (mmol/l) 4.8 ± 0.6 7.3 ± 1.0 7.4 ± 1.3 6.5 ± 1.0 5.8 ± 0.7 5.3 ± 0.7
P-proinsulin (pmol/l) 5.9 ± 7.4 17.1 ± 10.8 27.8 ± 14.6 29.7 ± 11.8 26.3 ± 8.9 19.9 ± 10.8
P-insulin (pmol/l) 19.8 ± 13.2 190 ± 91.2 196 ± 97.2 147 ± 67.8 88.8 ± 37.8 52.2 ± 38.4
P-FFA (mmol/l) 0.78 ± 0.32 0.69 ± 0.27 0.38 ± 0.23 0.26 ± 0.11 0.29 ± 0.19 0.29 ± 0.14
P-TG (mmol/l) 0.91 ± 0.65 0.95 ± 0.89 1.03 ± 0.97 1.07 ± 1.02 1.07 ± 0.96 1.08 ± 0.81
Data given are arithmetic means (SD).
P, Plasma; FFA, free fatty acids; TG, triglycerides; MO, morbidly obese; GBP, gastric bypass; NW, normal weight.
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FIGURE 1 The postprandial changes in glucose (a), proinsulin (b), insulin (c), free fatty acid (FFA) (d) and triglyceride (TG) (e) concentrations are shown 
for 180 min after the ingestion of the standardized test meal (mean ± SEM).  , Morbidly obese (MO) subjects;  , MO subjects treated with gastric bypass 
(GBP) surgery;  , normal weight (NW) control subjects. Glucose: a rapid increase in glucose concentration during the first 30–60 min (early phase) 
was observed in the GBP-treated group compared with MO subjects (30 min, P < 0.001; 60 min, P = 0.002) and NW control subjects (30 min, 
P < 0.001; 60 min, P = 0.015). In the late phase after ingestion (120–180 min), glucose was significantly lowered in the GBP-treated group compared 
with MO subjects (120 min, P = 0.009; 180 min, P = 0.004) and NW control subjects at 180 min (P = 0.02). Proinsulin: at all postprandial time points, 
except at 30 min, proinsulin concentrations were higher in MO than in control subjects (P = 0.030–0.008). Early-phase proinsulin concentrations were 
higher in the GBP-treated group compared with control subjects (30 min, P = 0.002; 60 min, P = 0.006), but were similar to the MO group. In the late 
phase, concentrations of plasma proinsulin were significantly lower in the GBP-treated group compared with the MO group (120 min, P = 0.048; 
180 min, P = 0.009), and the GBP-treated group had similar concentrations to control subjects (120 min, P = 0.307; 180 min, P = 0.814). Insulin: the 
GBP-treated group had a rapid increase in insulin concentration at 30 min in the early phase that had decreased at 60 min (30 min, P = 0.001; 60 min, 
P = 0.026) compared with control subjects. The late-phase insulin response was significantly higher in the MO group compared with the GBP-treated 
group (120 and 180 min, P < 0.001). Insulin concentrations during the late phase in the GBP-treated group did not differ from control subjects (120 min, 
P = 0.072; 180 min, P = 0.130). Free fatty acids: no differences were observed regarding postprandial changes between the three groups, except at 
180 min, where FFA were higher in the GBP group (P = 0.016). Triglycerides: no differences were observed regarding postprandial changes between 
the three groups, except at 180 min, where TG were higher in the MO group (P < 0.001).
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=  0.07). TG absolute concentrations, presented in Table  2,
were significantly higher (P = 0.06–0.003) at each postprandial
time point in the MO group compared with the GBP group and
NW control subjects. No significant differences were observed
regarding postprandial changes in circulating TG and con-
centrations between the three groups, except at 180 min, where
TG were higher in the MO group (Fig. 1e).
Pearson product moment correlation coefficients
BMI correlated with AUC for proinsulin (r2 = 0.19, P = 0.006)
and with AUC for insulin (r2 = 0.35, P < 0.001), but not with
AUC for glucose (r2 = 0.03, P = 0.34), AUC for FFA (r2 = –0.03,
P = 0.87) or AUC for TG (r2 = 0.06, P = 0.15).
Gender comparisons
Fasting glucose, proinsulin, insulin, FFA and TG did not differ
between men and women in the three groups. There were no
differences between men and women regarding changes in
glucose, proinsulin, insulin, proinsulin to insulin ratio, FFA or
TG during the postprandial phases within the three groups.
Discussion
Postprandial proinsulin concentrations in GBP-treated subjects
were lower than in obese subjects, but higher than in normal
weight control subjects when expressed as the AUC, but
notably proinsulin concentrations were normalized 180 min
postload. In the GBP group, a rapid rise in glucose concentra-
tions during the early postprandial phase was followed by a
rapid decline ending in even lower concentrations in the later
phase than in NW control subjects. The AUCs for glucose over
the 180 min studied were similar in all three groups. The rapid
emptying of the meal directly into the small intestine without
the normal gastric lag time delay may partly explain the pattern
of glucose response in the GBP group.
The rapid rise in glucose induced a rapid response, i.e. a rise
in proinsulin concentrations in the early phase with a peak at
60 min in the GBP group. The corresponding peak in the MO
group was seen at 120 min and in this group postprandial
proinsulin concentrations were persistently high throughout
the 180-min postload period, reflecting a high demand on
pancreatic B-cell secretion.
The high fasting proinsulin concentrations in the MO
participants, indicating insulin resistance, were significantly
lowered in the GBP group and similar to NW control subjects,
indicating improved insulin sensitivity by the induced weight
loss in the group treated with bariatric surgery. Weight loss is
more pronounced after GBP surgery than after gastric banding
[17,19]. GBP surgery also improves the entero-insular axis
and glucagon-like peptide-1 secretion [20]. Gastric banding
reduces fasting proinsulin concentrations by up to 50%, but
does not normalize them [21]. In the present study, markedly
lowered proinsulin concentrations were observed in the GBP
group, almost similar to those in normal control subjects in the
fasting and late phase after ingestion, clearly indicating
increased and almost normalized insulin sensitivity and thus
markedly reduced B-cell demand.
Previously, insulin concentrations and not proinsulin have
been analysed in meal tolerance or glucose tolerance studies
of obese subjects or obese subjects who had undergone GBP
surgery [22,23]. One pilot study which measured proinsulin
concentrations after a test meal in obese compared with
normal control subjects was too small to be conclusive [24].
The present study analysed glucose, proinsulin, insulin and
the proinsulin to insulin ratio after a standardized test meal
where effort was made to compose a test meal representing an
‘every-day lunch’ for GBP-treated subjects. The caloric content
was 2400 kJ, which is similar to that of a 75-g oral glucose
tolerance test (OGTT). The rapid glucose rise observed in the
GBP group induced a rapid insulin response that peaked at
30  min postload, followed by relative hypoinsulinaemia
during the latter half of the test. The first 30–60 min of a test
meal or an OGTT reflect the first phase of insulin secretion,
which has an important role in switching metabolic processes
between fasting and postprandial states, mainly by inhibiting
hepatic glucose production. A poor or inappropriate first phase
of insulin secretion is associated with unsuppressed postprandial
glucose production, leading to subsequent higher postprandial
glycaemia [25]. Abnormal first-phase insulin secretion is
associated with an increased risk of T2DM [26–28] and
elevation of the proinsulin to insulin ratio [29], which is
also related to T2DM development [30]. In the present study
of subjects free of diabetes, the fasting proinsulin to insulin
ratios did not differ between groups and decreased similarly
after ingestion in all three groups during the early phase,
indicating an intact first-phase insulin release, similar to
findings using the hyperglycaemic clamp in obese subjects free
of diabetes [31].
When studying changes at each time point of the test meal,
analysing proinsulin and insulin, we were able to analyse early as
well as late responses that were not fully seen when comparing
AUCs between groups. The postload AUCs of proinsulin and
insulin correlated with fasting concentrations of proinsulin,
insulin and BMI, and thus to a great extent reflected the degree
of insulin sensitivity. In the MO group, proinsulin concentra-
tions were persistently high during the entire 180-min test.
This observation, taking into account the contributory factor
of the substantially longer half-life, 115 min for proinsulin
compared with 5 min for insulin [32], and that regular meals
are often ingested at 3–4-h intervals during the day, might
indicate that meal-induced B-cell strain contributes to raised
proinsulin throughout a substantial period of the day in
obesity. It remains unknown whether such elevated post-
prandial proinsulin concentrations are associated with increased
risk of type T2DM [5–7] or CHD [8–10], as has been reported
for fasting concentrations.
In obesity, insulin resistance is common and precedes the
progression to impaired glucose tolerance (IGT) and T2DM
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[33]. Fasting proinsulin concentrations are elevated in the IGT
state, but also precede the prediabetic state of IGT [34] and are
an independent predictor for T2DM. Surgical treatment with
GBP in obese subjects improves insulin sensitivity [14] even
though patients are still obese [15]. A novel finding in the
present study was the markedly lowered fasting proinsulin and
the postprandial proinsulin response that were normalized at
180 min after the test meal, indicating lowered B-cell demand
throughout the test and also reflected by the relative hypo-
insulinaemia in the late phase postload (Fig. 1c). As expected,
fasting and postprandial FFA and TG absolute concentrations
were higher in the MO group throughout the test, but a differ-
ence in changes of FFA or TG was observed only at 180 min,
when FFA changes were highest in the GBP-treated group,
possibly due to low inhibition of lipolysis caused by a state of
relative hypoinsulinaemia. Lowest absolute values of FFA were
observed in the GBP group at all time points up to 120 min
because of the insulin peak and secretion, which strongly
suppress lipolysis up to this time point.
The relative hypoinsulinaemia in the late phase of the test in
the GBP group followed the rapid decrease in both glucose and
insulin after peak concentrations in the early phase, and
coincided with the time point when symptoms of the so-called
dumping syndrome may occur [16]. The mechanisms behind
gastric discomfort and fatigue are not fully understood, but the
rapid shift in glucose and insulin concentrations, relative
hypoinsulinaemia and hypoglycaemia may contribute to such
symptoms [16,35].
In summary, GBP surgery results in dramatically improved
insulin sensitivity and rapid meal-stimulated secretions of
proinsulin and insulin with sustained effects on glucose and
lipid metabolism. Our results suggest that future studies should
determine whether proinsulin is a marker for diabetes risk
before and after GBP surgery. It might be speculated that the
proinsulin status can be used as an indication for bariatric
surgery. To answer such questions, further research on proinsulin
and insulin as markers for T2DM and CHD in long-term
follow-up after GBP surgery is warranted.
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